TauRx Pharmaceuticals Ltd: Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published researchSafety profile

Related Keywords

Malaysia ,United Kingdom ,Singapore ,Kostenloser Wertpapierhandel ,Claude Wischik ,Genting Taurx Diagnostic Centre Sdn Bhd ,Gt Diagnostics United Kingdom ,Global Conference Of Alzheimer Disease International ,University Of Aberdeen ,Taurx Pharmaceuticals Ltd Group ,Regulatory Agency ,Genting Berhad ,Taurx Therapeutics Ltd ,Taurx Pharmaceuticals Ltd ,Executive Chairman ,Global Conference ,United Kingdom Medicines ,Innovation Passport ,Innovative Licensing ,Access Pathway ,Mild Cognitive Impairment ,Taurx Diagnostic Centre Sdn Bhd ,Taurx ,Pharmaceuticals ,Targeting ,Lzheimer ,Treatment ,Imtm ,Moving ,Howard ,Egulatory ,Submission ,Ased ,Nitial ,Data ,Rom ,Lucidity ,Trial ,